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Sir
We read with interest the report of Cote and colleagues (Cote et al,
1998) regarding the series of 52 men at risk of prostate cancer who
received finasteride, or were observed and then biopsied after a
1-year period. The population of patients were at high risk for
prostate cancer, despite an initial negative biopsy, by virtue of a mean
baseline prostate-specific antigen (PSA) of 9.18 and 10.30 ng ml—1
respectively, and 8/27 and 5/25 with prostatic intraepithelial
neoplasia (PIN) on initial biopsy. Their results indicated no signifi-
cant change in proliferation cell nuclear antigen (PCNA) index but a
prostate cancer detection rate of 30% compared to 4% in patients
treated with finasteride or controls respectively. For this reason, the
authors conclude that, ￿This study raises serious questions about the
probable efficacy of finasteride in preventing prostate cancer￿.
The authors￿ concern is of importance as the National Cancer
Institute is currently sponsoring the Prostate Cancer Prevention
Trial (PCPT) which is assessing the ability of finasteride to
prevent prostate cancer in a population of 18 882 men who are
without disease by virtue of a PSA † 3.0 ng ml—1 and a normal
digital rectal examination. The rationale for the potential efficacy
of finasteride in the prevention of prostate cancer has been
described previously in detail (Gormley et al, 1995; Thompson et
al, 1997). Although the findings of Cote are of interest, serious
concerns regarding the study and its results should be understood.
While in the design of the PCPT the statistical assumptions
called for a 90% power to detect a 25% reduction in incidence of
prostate cancer, assuming a placebo-positive biopsy rate of 6%
and a two-sided alpha of 0.05, it is unclear what study assumptions
of the investigators led to a sample size of 52. It is certain,
however, that small sample size studies can often lead to spurious
results. For example, in the Cote study, if rather than 8/27 and 1/25
patients with positive biopsies, the rates were 7/27 and 1/25, the P-
value would change from 0.025 to 0.051. This is even more
dramatic when the patients with PIN are removed from the sample
— the resulting patients had rates of 2/19 and 1/20 — a meaningless
difference in prostate cancer rates.
Perhaps most of concern is the prostate cancer diagnosis rate
among controls in Cote￿s study. In this group of patients with a mean
PSA of 10.30 ng ml—1, of whom five had PIN on pre-study biopsy,
only one (4%) had a positive 1-year biopsy. This is most interesting
as many authors in much larger series of patients have reported that
rates of positive second sextant biopsies of patients with persistently
elevated PSA have ranged from 13% to 26% (Keetch et al, 1994;
Eskey et al, 1997; Niesel et al, 1997). If one looks for patients more
akin to those of Cote, one group of men with PSAs > 10 had a 33%
rate of positive-biopsy and another group of 48 men with high-grade
PIN had a 47.9% rate of positive re-biopsy (Keetch et al, 1994; Raviv
et al, 1996). The sum of these data suggest that the 30% prostate
cancer detection rate in the very high-risk group of patients who were
randomized to receive finasteride was to be expected. What is diffi-
cult to explain is the extraordinarily low rate of prostate cancer in the
controls. One must assume that an unknown source of bias was oper-
ational as the most likely explanation or that this finding represents
the play of chance attributable to the small study size.
Apropos to this, the recent publication of 4-year follow-up data
of 3020 men randomized to placebo or finasteride found equivalent
rates of cancer detection in both study arms (McConnel et al, 1998).
Evidence continues to develop that finasteride may have a preven-
tive role in patients who are at risk of prostate cancer (Tsukmoyo et
al, 1998). The results of the Prostate Cancer Prevention Trial will
have enough power to address this extremely important issue.
CA Coltman
Southwest Oncology Group,
14980 Omicron Drive, San Antonio,
TX 78245-3217, USA
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Sir
The letter by Dr Coltman raises a number of important issues
regarding our recent paper (Cote et al, 1998). As the first group to
propose that 5a-reductase inhibitors might prove efficacious in
prostate cancer prevention (Ross et al, 1992), we are well aware ofLetters to the Editor 185
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Sir
It was with great interest that we read the letter to the Editor from
Vermeulen et al (1999) regarding the accuracy of the measurement
of vascular endothelial growth factor (VEGF) serum levels
(VEGF-SL) and VEGF plasma levels (VEGF-PL) in cancer
patients (Vermeulen et al, 1999). We have measured about 1000
serum samples for VEGF and should thus like to comment on their
observations based on our findings:
1. We agree with Vermeulen et al that interindividual and intra-
individual fluctuations of serum VEGF levels can, at least in
part, be explained by variations of blood platelet counts.
Another factor that may contribute to the variability of serum
VEGF levels is the platelet volume. This notion is substanti-
ated by our findings from patients receiving myeloablative
chemotherapy. In these patients, screening of VEGF-SL was
begun prior to the platelet nadir (< 20 G l—1) and continued
until the platelet counts had been recovered. VEGF was
measured in 140 serum samples and 54 corresponding plasma
samples by enzyme-linked immunosorbent assay (ELISA),
essentially as described by Vermeulen et al. In line with their
results, we found a striking correlation between peripheral
blood platelet counts and absolute values of VEGF-SL (r =
0.8; P < 0.001), but not with VEGF-PL. Like Vermeulen and
colleagues, we noted a broad inter-individual and intra-indi-
vidual variability of VEGF-SL values. Thus, we hypothesized
that VEGF-SL may not only depend on blood plaletet counts
but also on the plaletet size. Platelets freshly released from the
bone marrow following myeloablative chemotherapy may
differ in size from those produced during a steady-state of
myelopoiesis. To test this hypothesis, we compared the mean
platelet volumes (MPV) prior to the platelet nadir with the
MPV during the time of platelet reconstitution by using an
electronic particle counter. In peripheral blood, the MPV
before the platelet nadir indeed proved to be significantly
lower than afterwards. Even if VEGF-SL values were
corrected for the actual blood platelet count (VEGFPLT =
VEGF-SL ´ 106 platelets/actual blood platelet count),
VEGFPLT values prior to the platelet nadir were significantly
lower than those measured afterwards (Figure 1).
2. In vivo, platelet activation or platelet destruction causes major
increments in VEGF blood levels: we detected high VEGF
levels in both serum and plasma samples indicating a massive
release of VEGF during intravasal platelet destruction in a
patient with thrombotic-thrombocytopenic purpura.
3. Tumour cells and/or blood platelets may be the major sources
of VEGF in cancer patients, particularly in metastatic disease.
In fact, the majority of cancer patients with metastatic disease
show elevated VEGF levels in serum (Kraft et al, 1999).
Moreover, increasing VEGF serum levels may herald tumour
relapse or progression. In a patient with breast cancer under-
going adjuvant high-dose chemotherapy, we noted a rapid
the rationale for the potential efficacy of finasteride in preventing
prostate cancer. We began our study fully expecting to observe
beneficial effects on prostate cancer. Unfortunately we did not.
Although, we, too, were somewhat surprised by the low inci-
dence of prostate cancer in the observational arm at the 1-year
follow-up biopsy, we doubt that Coltman would have found
acceptable a trial utilizing possibly inappropriate historical
controls. The notion that you can change an observation in a trial
and modify statistical values is hardly novel, and belies the entire
purpose of statistical testing. Coltman raises the issue that if the
cancer detection rate had been 7/27 and 1/25 in the treated and
untreated groups, the P-value of the difference would be 0.051.
Although this does not reach ￿statistical significance￿, we would
have considered such a difference to be very worrisome.
Coltman then states that if the patients with PIN are removed,
the difference in cancer detection rates is meaningless. Two points
can be made: (1) a clear and important conclusion of our study is
that the presence of PIN is a strong risk factor for developing a
positive biopsy after finasteride treatment; (2) in men without PIN
the effect of finasteride on the diagnosis of prostate cancer is
￿meaningless￿ because of small numbers. However, the much
larger study referred to by Coltman of McConnel et al (1998) did
not find a protective effect of finasteride either. In the latter trial, a
total of 3040 men were randomized to receive finasteride or
placebo for the treament of symptoms of benign prostatic hyper-
plasia. Treatment was for 4 years; in order to monitor for prostate
cancer, 645 men underwent prostate biopsies during the study (325
men in the finasteride group and 320 men in the placebo group).
The incidence of prostate cancer was 5% in each group, indicating
no reduction in prostate cancer risk in a large population of lower
risk men undergoing long-term treatment with finasteride.
Coltman repeatedly points to the small size of our trail.
However, we were faced with the serious dilemma in the interim
analysis of our study, that we might be causing harm. We decided
that we could not justify continuing to accrue additional subjects.
Our trial, while small, remarkably provides the only data of any
kind to date on the biological effects of finasteride on human
prostate tissue. We strongly feel that studies such as ours are essen-
tial before embarking on large scale, long-term multi-institutional
trials in healthy individuals. We undertook our study because of
the dearth of any such relevant information.
As Chairman of the Southwest Oncology Group under whose
auspices the US National Prostate Cancer Prevention Trial is being
conducted, we believe the results of our study merit Dr Coltman￿s
attention, and should not be dismissed on dubious statistical grounds.
RK Ross, MC Pike, E Skinner and RJ Cote
University of Southern California, School of Medicine,
1441 Eartlake Avenue, Los Angeles, CA 90033-0800, USA
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